Is there a Wegovy pill? Oral semaglutide, explained

Is there a Wegovy pill now?

Yes. After years of headlines about a possible tablet, the FDA approved the Wegovy pill in December 2025 for reducing excess body weight, maintaining weight reduction and lowering the risk of major cardiovascular events in adults with obesity or overweight plus a weight-related condition.

It is a once-daily tablet containing 25 mg of semaglutide, the same active molecule as the Wegovy injection. Novo Nordisk launched it in the US in early January 2026 and announced a cash price starting around $149 for a month's supply through its direct pharmacy channel.

Approvals elsewhere followed through 2026, with the European Union joining the list in July. By then the tablet was already on sale in the United Kingdom and the United Arab Emirates as well as the US, and further launches were planned for the second half of the year.

The pill matters beyond convenience. Tablets need no needles, no fridge and simpler manufacturing than injection pens, so a working oral GLP-1 could eventually widen access in markets where cold-chain supply and pen production have been the bottleneck.

Where else is the Wegovy pill approved now?

The European Commission approved the Wegovy pill on 15 July 2026 for adults with obesity, or overweight plus at least one weight-related condition. Novo Nordisk called it the fifth regulatory approval for the tablet, which was already available in the United States, the United Kingdom and the United Arab Emirates, and said launches in EU countries would follow in the second half of 2026.

The EU authorisation covers four tablet strengths, 1.5 mg, 4 mg, 9 mg and 25 mg, which shows how dosing works in practice: treatment starts low and steps up to the 25 mg maintenance dose, the same escalation logic as the injection.

On the same day the Commission approved a higher-strength Wegovy injection, 7.2 mg in a single-dose pen. That belongs to the injectable line rather than the pill, but it illustrates where the product family is heading: more strengths and more formats, arriving market by market.

None of this changes the South African position by itself. Each major approval does, however, grow the dossier a manufacturer can bring to SAHPRA, which feeds the timeline question below.

Can you get the Wegovy pill in South Africa?

No. The Wegovy pill is not registered with SAHPRA, so it cannot legally be sold in South Africa, and no local launch date has been announced. The only Wegovy registered here is the once-weekly injection, which launched in August 2025.

That gap between US approval and SA availability is normal. A manufacturer must submit the product to SAHPRA, wait out the review, then set up local supply. Wegovy's injectable form took about four years from its first US approval to reach South African pharmacies.

Be careful with anyone claiming otherwise. If a website, salon or social media seller offers "Wegovy tablets", "semaglutide capsules" or "GLP-1 drops" in South Africa today, the product is not a registered medicine. SAHPRA has warned repeatedly about falsified semaglutide, and unregistered products have no verified contents at all.

In the meantime, South Africans who qualify for treatment have registered once-weekly injectable options, and a doctor can advise which, if any, fits your health picture. Waiting for a tablet that has no local timeline is rarely a better plan than treating obesity with what is registered now.

How long does SAHPRA registration usually take?

There is no fixed clock, but the published record gives a range. A 2023 study in the Journal of Pharmaceutical Policy and Practice found that medicine registration historically took years under the old Medicines Control Council, with new medicines commonly waiting five to seven years, and that the backlog programme brought typical turnaround down to around 18 months by the time the inherited backlog was cleared in 2022.

SAHPRA also uses reliance pathways: where regulators it recognises, such as the EMA or FDA, have already assessed a medicine, SAHPRA can build on those reviews rather than repeat every step. For a product with five major approvals already, that route is designed to shorten the wait.

The sequence would run: Novo Nordisk submits an application, SAHPRA evaluates and registers, then the company decides whether and when to launch. That last step is the wildcard. Rybelsus, the diabetes tablet, was registered in 2024 and has still not been launched here, so registration alone does not put a medicine on shelves.

Novo Nordisk had not announced a South African submission or timeline for the tablet at the time of writing, so any local date is guesswork. The injectable form remains the registered route in the meantime, and what to expect from treatment covers how doctor-led care around it works.

What about Rybelsus, the other semaglutide tablet?

Rybelsus is the original oral semaglutide, taken daily in 3 mg, 7 mg and 14 mg strengths. It is registered for type 2 diabetes, not for weight management, and its doses are far lower than the 25 mg in the Wegovy pill.

SAHPRA registered Rybelsus in 2024, but Novo Nordisk has not launched it into South African pharmacies, and the company has not announced timing. So even the diabetes tablet is not something you will find on a local shelf right now, and it has never carried a weight-loss registration anywhere.

In short: two semaglutide tablets exist globally, one for diabetes and one for weight management, and neither is currently available in South Africa.

The EU approval put the difference into plain numbers: 1.5 mg to 25 mg strengths for the weight-management tablet against 3 mg to 14 mg for Rybelsus. Different strengths, different escalation, different registered jobs. If someone offers "semaglutide tablets" for weight loss at Rybelsus-style strengths, that is a double warning: the wrong product for the purpose, and almost certainly not a registered one.

How does oral semaglutide work?

The tablet delivers the same GLP-1 receptor agonist as the injection: it curbs appetite, slows stomach emptying and helps regulate blood sugar. Our guide to what semaglutide is and how it works covers the mechanism in detail.

Getting a peptide through the stomach intact is the hard part, which is why the tablet includes an absorption enhancer called SNAC and comes with strict rules: take it when you wake, on an empty stomach, with a few sips of plain water, then wait about 30 minutes before eating, drinking or taking other oral medicines.

That routine is the main practical trade-off. The injection asks for one moment a week; the tablet asks for a disciplined start to every single day. Neither is better in the abstract, they just suit different people.

What does the tablet routine look like day to day?

The absorption rules shape the whole morning. The tablet is taken on waking, on an empty stomach, with a few sips of plain water, then nothing else by mouth for about 30 minutes: no coffee, no breakfast, no other tablets.

That last point matters for anyone on other morning medicines. Thyroid tablets, for example, also want an empty stomach, so the sequence has to be planned deliberately with a doctor. Solvable, but a conversation for the assessment rather than an afterthought.

Travel is where a tablet is simpler: no fridge, no cold chain, no cooler bag through airport security, and load shedding is irrelevant to a blister pack stored below 30 degrees.

Storage is the one rule the tablet relaxes. Keep the blister strip in its packaging, dry and below 30 degrees; a bedroom drawer beats a steamy bathroom cabinet.

Consistency is the price of that convenience. The OASIS 4 results describe people who took the tablet as intended, and skipped mornings dilute the effect. A weekly injection asks for one disciplined moment instead of a daily one; the right option is decided by a doctor on assessment.

Does the Wegovy pill work as well as the injection?

The trial data says the two are in the same range. In the OASIS 4 trial, adults taking the 25 mg tablet for 64 weeks lost an average of 16.6% of their body weight when the treatment was taken as intended, and about one in three lost 20% or more. Individual results vary.

That sits alongside the 14.9% average that the 2.4 mg weekly injection produced over 68 weeks in the STEP 1 trial, where individual results also varied. No head-to-head trial has compared tablet and injection directly, but regulators concluded the tablet's weight loss is broadly similar to the injection's.

One real caveat sits inside that 16.6% figure: it assumes the tablet was actually taken as intended every day. Daily tablets are easier to skip than weekly injections, and missed doses shrink results in the real world, which is why doctors care as much about the routine you can sustain as the number in the trial report.

Wegovy pill vs Wegovy injection at a glance

Individual results vary; the trial figures are averages from different studies with different designs, not a direct contest between the two products.

Could you switch from the injection to the pill later?

If the tablet reaches South African shelves, people already on the injection will ask about moving across. Switching between forms of the same molecule is a doctor-managed change, not a swap at the pharmacy counter: the dose ladders differ, and the daily routine has to be workable before the change makes sense.

The general principles for any change between GLP-1 medicines apply: a review of how you are responding, a planned start on the new form at an appropriate dose, and follow-up while the change beds in. Nobody should run two semaglutide products at once, whatever their format.

A doctor manages that process step by step, including deciding when staying put is the better answer.

What would the Wegovy pill cost?

There is no South African price because there is no South African registration. In the US it launched at around $149 per month as a cash price through Novo Nordisk's direct channel, notably cheaper than US injectable list prices, and analysts expect tablet pricing to undercut injections in most markets because tablets are cheaper to make and ship.

European launch prices had not been announced at the time of writing, and a South African price would only be set through the Single Exit Price system after registration, so any rand figure you see today for the tablet is invented. We do not sell medicine. Prices vary by pharmacy and dose; confirm with your pharmacy.

For what weight-loss treatment actually costs here and now, see how much Wegovy costs in South Africa. As always with medicine costs, prices vary by pharmacy and dose; confirm with your pharmacy.

What other weight-loss pills are in the pipeline?

The Wegovy pill is no longer alone. The US FDA approved orforglipron, Eli Lilly's once-daily tablet sold there as Foundayo, on 1 April 2026 for weight management in adults. It is a small molecule rather than a peptide, which means no food or water restrictions around the daily dose and simpler manufacturing at scale.

Lilly said it had filed orforglipron for approval in more than 40 countries. As with the Wegovy pill, there is no SAHPRA registration yet, so neither tablet can legally be sold in South Africa, and no local timeline has been announced for either.

Behind those two sit further oral candidates in late-stage trials from several manufacturers. The direction is clear: over the next few years, tablets will compete with injections in weight management globally, and competition between them will shape prices and availability everywhere, including here eventually.

One caution keeps its place through all of this. A busy pipeline does not legitimise anything sold today as a "GLP-1 pill" outside a pharmacy. Until a tablet is registered here, every local offer of one is an unregistered product with unverified contents, and SAHPRA's warnings apply in full.

Side effects of oral semaglutide

The tablet carries the same main side effects as injectable semaglutide: nausea, vomiting, diarrhoea, constipation and stomach discomfort, most noticeable in the early months and around dose changes. Most cases are mild to moderate and settle with time, smaller meals and enough fluids.

The same exclusions apply too. It is not for use in pregnancy, while breastfeeding, or by people with a personal or family history of medullary thyroid cancer or MEN2, and anyone with a history of pancreatitis needs a careful medical decision. Severe, persistent stomach pain on any semaglutide product can signal pancreatitis: seek medical care immediately.

Whichever form eventually suits you, semaglutide is a Schedule 4 medicine in South Africa: a doctor must assess you and confirm a treatment plan before a licensed pharmacy can dispense it. If you are weighing semaglutide against the other main option, read our semaglutide vs tirzepatide comparison.

Frequently asked questions